SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Vickers Andrew J.)
 

Sökning: WFRF:(Vickers Andrew J.) > Association Between...

  • Assel, MelissaMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA (författare)

Association Between Lead Time and Prostate Cancer Grade : Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening

  • Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

  • Elsevier BV,2018
  • 7 s.

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:bea50a54-ff4f-4244-a070-ec9b48f514e4
  • https://lup.lub.lu.se/record/bea50a54-ff4f-4244-a070-ec9b48f514e4URI
  • https://doi.org/10.1016/j.eururo.2017.10.004DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-148723URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-336229URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Background: Lead time (LT) is of key importance in early detection of cancer, but cannot be directly measured. We have previously provided LT estimates for prostate cancer (PCa) using archived blood samples from cohorts followed for many years without screening. Objective: To determine the association between LT and PCa grade at diagnosis to provide an insight into whether grade progresses or is stable over time. Design, setting, and participants: The setting was three long-term epidemiologic studies in Sweden including men not subject to prostate-specific antigen (PSA) screening. The cohort included 1041 men with PSA of 3–10 ng/ml at blood draw and subsequently diagnosed with PCa with grade data available. Outcome measurements and statistical analysis: Multivariable logistic regression was used to predict high-grade (Gleason grade group ≥2 or World Health Organization grade 3) versus low-grade PCa at diagnosis in terms of LT, defined as the time between the date of elevated PSA and the date of PCa diagnosis with adjustment for cohort and age. Results and limitations: The probability that PCa would be high grade at diagnosis increased with LT. Among all men combined, the risk of high-grade disease increased with LT (odds ratio 1.13, 95% confidence interval [CI] 1.10–1.16; p < 0.0001), with no evidence of differences in effect by age group or cohort. Higher PSA predicted shorter LT by 0.46 yr (95% CI 0.28–0.64; p < 0.0001) per 1 ng/ml increase in PSA. However, there was no interaction between PSA and grade, suggesting that the longer LT for high-grade tumors is not simply related to age. Limitations include the assumption that men with elevated PSA and subsequently diagnosed with PCa would have had biopsy-detectable PCa at the time of PSA elevation. Conclusions: Our data support grade progression, whereby following a prostate over time would reveal transitions from benign to low-grade and then high-grade PCa. Patient summary: Men with a longer lead time between elevated prostate-specific antigen and subsequent prostate cancer diagnosis were more likely to have high-grade cancers at diagnosis. The probability that a cancer will be of high grade at diagnosis increases with the lead time. Our findings provide evidence of grade progression, whereby a prostate followed over time would exhibit transitions from benign to low-grade to high-grade prostate cancer.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Dahlin, AndersLund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups(Swepub:lu)infl-ada (författare)
  • Ulmert, DavidLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Univerity; Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA(Swepub:lu)klke-dul (författare)
  • Bergh, AndersUmeå universitet,Umeå University,Patologi(Swepub:umu)anbe0010 (författare)
  • Stattin, PärUppsala universitet,Urologkirurgi,Umeå University,Uppsala University Hospital,Norrland University Hospital(Swepub:uu)parst892 (författare)
  • Lilja, HansLund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,Lund University; University of Oxford; Memorial Sloan Kettering Cancer Center, New York, NY, USA,University of Oxford(Swepub:lu)klke-hli (författare)
  • Vickers, Andrew J.Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA (författare)
  • Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USAInternmedicin - epidemiologi (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:European Urology: Elsevier BV73:6, s. 961-9670302-28381873-7560

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy